#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Blood iron increased Inclusion body myositis Ornithine transcarbamoylase deficiency Leiomyosarcoma recurrent Thrombotic microangiopathy Uveitis Pulmonary arterial hypertension Adrenoleukodystrophy Neuroendocrine carcinoma metastatic Hyperchylomicronaemia Ovarian cancer Mucopolysaccharidosis I Colon cancer Macular telangiectasia Mitochondrial DNA depletion More trials…

    Learn about Rare Diseases

    Alport’s syndrome – Treatment Marfan’s syndrome Myxofibrosarcoma – Diagnostics Idiopathic inflammatory myopathy – Life with Disease VEXAS syndrome – Life with Disease Mantle cell lymphoma stage II – Basic Information Pleural mesothelioma malignant – Treatment Adrenogenital syndrome – Basic Information Hypereosinophilic syndrome Mantle cell lymphoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [18F]Fapi-74 Fipaxalparant Sodium Chloride Solution 0.9% Sulfasalazine Cebsulfase Alfa Glepaglutide PETHIDINE HYDROCHLORIDE Mercaptopurine Monohydrate Sepiapterin Gemtuzumab Ozogamicin ALN-4324 Tiapride Nilutamide Venlafaxine Hydrochloride Citric Acid KETOROLAC TROMETAMOL Dabigatran Inaxaplin Candesartan Doxycycline Monohydrate More therapies…

    Learn about Your Condition

    Post-acute COVID-19 syndrome Pneumothorax Pyelonephritis acute Hypoglycaemia Immune-mediated myositis Hand fracture Pelvic venous thrombosis Penile cancer Actinic keratosis Gaucher's disease type I Prostate cancer metastatic Pyelonephritis Small cell lung cancer Breast cancer stage III Cardiac failure congestive More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Arteriosclerosis

  • Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Ly3819469 Sodium
    Czechia Hungary The Netherlands Spain

  • A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Estonia France +10

  • A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

    Recruiting

    3 1
    Denmark France Germany Italy The Netherlands Spain

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Maridebart Cafraglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study on Atorvastatin to Prevent Atherosclerosis Progression in Patients Undergoing Immune Checkpoint Inhibitor Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Atorvastatin
    • Placebo
    The Netherlands
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!